[Study of clinical outcome and prognosis in pediatric core binding factor-acute myeloid leukemia]

J Wu, A D Lu, L P Zhang, Y X Zuo, Y P Jia, J Wu, A D Lu, L P Zhang, Y X Zuo, Y P Jia

Abstract

Objective: To analyze the clinical outcome and the prognostic factor in pediatric patients with core binding factor-acute myeloid leukemia (CBF-AML). Methods: A total of 121 newly diagnosed pediatric CBF-AML patients enrolled from Aug. 2005 to Sep. 2017 were retrospectively reviewed. Cumulative incidence of relapse (CIR), event-free survival (EFS) and overall survival (OS) rates were estimated by Kaplan-Meier method and prognostic factors were evaluated by Cox regression with SPSS. Results: Of the 121 patients, 120 patients were assessed for bone marrow remission after induction chemotherapy. 100 cases (83.3%) achieved complete remission (CR) after the first course of chemotherapy. 119 cases (99.2%) achieved CR after the second course of chemotherapy. Of the 121 patients, 13 patients (10.7%) had recurrence with the median interval of recurrence as 13.8 months (3.7 to 58.8 months). 17 patients (14.0%) died. The CIR, EFS and OS at 3 years were 12.7%, 77.5% and 82.8%, respectively. The factors including age at diagnosis, sex, initial WBC count, presence of extramedullary leukemia, C-KIT expression, additional chromosomal abnormalities, and CR after the first course of chemotherapy were analyzed by multivariate regression analysis of Cox. Multivariate analysis identified that additional chromosomal abnormalities was the only independent risk factor affecting OS (HR=4.289, 95%CI 1.070-17.183, P=0.040). Conclusions: Pediatric CBF-AML was a unique setting of prognostic subtypes. Chemotherapy produced good responses. Additional chromosomal abnormalities was the only independent risk factor for OS in pediatric CBF-AML.

Keywords: Childhood; Core binding factor; Leukemia, myeloid, acute; Prognosis DOI: 10.3760/cma.j.issn.0253-2727.2019.01.010.

Figures

图1. 121例核心结合因子相关性急性髓系白血病患者无事件生存及总生存曲线
图1. 121例核心结合因子相关性急性髓系白血病患者无事件生存及总生存曲线

References

    1. Pui CH, Carroll WL, Meshinchi S, et al. Biology, risk stratification, and therapy of pediatric acute leukemias: an update[J] J Clin Oncol. 2011;29(5):551–565. doi: 10.1200/JCO.2010.30.7405.
    1. Imamura T, Iwamoto S, Kanai R, et al. Outcome in 146 patients with paediatric acute myeloid leukaemia treated according to the AML99 protocol in the period 2003-06 from the Japan Association of Childhood Leukaemia Study[J] Br J Haematol. 2012;159(2):204–210. doi: 10.1111/bjh.12030.
    1. 车 琳, 许 云云, 庞 丽, et al. 核因子阳性儿童急性髓细胞性白血病临床特征及预后因素分析[J] 中华实用儿科临床杂志. 2014;29(3):207–211. doi: 10.3760/cma.j.issn.2095-428X.2014.03.013.
    1. 中华医学会儿科学分会血液学组, 《中华儿科杂志》编辑委员会. 儿童急性髓细胞白血病诊疗建议[J] 中华儿科杂志. 2006;44(11):877–878. doi: 10.3760/j.issn:0578-1310.2006.11.023.
    1. 秦 亚溱, 李 金兰, 主 鸿鹄, et al. 实时定量RT-PCR技术测定初治白血病患者常见融合基因转录子水平及其标准化的探讨[J] 中华血液学杂志. 2007;28(7):433–437.
    1. Qin YZ, Zhu HH, Jiang Q, et al. Prevalence and prognostic significance of c-KIT mutations in core binding factor acute myeloid leukemia: a comprehensive large-scale study from a single Chinese center[J] Leuk Res. 2014;38(12):1435–1440. doi: 10.1016/j.leukres.2014.09.017.
    1. Rulina AV, Spirin PV, Prassolov VS. Activated leukemic oncogenes AML1-ETO and c-kit: role in development of acute myeloid leukemia and current approaches for their inhibition[J] Biochemistry (Mosc) 2010;75(13):1650–1666. doi: 10.1134/S0006297910130092.
    1. 张 之南, 沈 悌. 血液病诊断及疗效标准[M] 3版. 北京: 科学出版社; 2007. pp. 214–218.
    1. Zwaan CM, Kolb EA, Reinhardt D, et al. Collaborative efforts driving progress in pediatric acute myeloid leukemia[J] J Clin Oncol. 2015;33(27):2949–2962. doi: 10.1200/JCO.2015.62.8289.
    1. Klein K, Kaspers G, Harrison CJ, et al. Clinical impact of additional cytogenetic aberrations, cKIT and RAS mutations, and treatment elements in pediatric t(8;21)-AML: results from an international retrospective study by the International Berlin-Frankfurt-Münster Study Group[J] J Clin Oncol. 2015;33(36):4247–4258. doi: 10.1200/JCO.2015.61.1947.
    1. Duployez N, Marceau-Renaut A, Boissel N, et al. Comprehensive mutational profiling of core binding factor acute myeloid leukemia[J] Blood. 2016;127(20):2451–2459. doi: 10.1182/blood-2015-12-688705.
    1. Hoyos M, Nomdedeu JF, Esteve J, et al. Core binding factor acute myeloid leukemia: the impact of age, leukocyte count, molecular findings, and minimal residual disease[J] Eur J Haematol. 2013;91(3):209–218. doi: 10.1111/ejh.12130.
    1. Balgobind BV, Hollink IH, Arentsen-Peters ST, et al. Integrative analysis of type-I and type-II aberrations underscores the genetic heterogeneity of pediatric acute myeloid leukemia[J] Haematologica. 2011;96(10):1478–1487. doi: 10.3324/haematol.2010.038976.
    1. Pollard JA, Alonzo TA, Gerbing RB, et al. Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML[J] Blood. 2010;115(12):2372–2379. doi: 10.1182/blood-2009-09-241075.
    1. Goemans BF, Zwaan CM, Miller M, et al. Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia[J] Leukemia. 2005;19(9):1536–1542. doi: 10.1038/sj.leu.2403870.
    1. Shih LY, Liang DC, Huang CF, et al. Cooperating mutations of receptor tyrosine kinases and Ras genes in childhood core-binding factor acute myeloid leukemia and a comparative analysis on paired diagnosis and relapse samples[J] Leukemia. 2008;22(2):303–307. doi: 10.1038/sj.leu.2404995.
    1. Cher CY, Leung GM, Au CH, et al. Next-generation sequencing with a myeloid gene panel in core-binding factor AML showed KIT activation loop and TET2 mutations predictive of outcome[J] Blood Cancer J. 2016;6(7):e442. doi: 10.1038/bcj.2016.51.
    1. Manara E, Bisio V, Masetti R, et al. Core-binding factor acute myeloid leukemia in pediatric patients enrolled in the AIEOP AML 2002/01 trial: screening and prognostic impact of c-KIT mutations[J] Leukemia. 2014;28(5):1132–1134. doi: 10.1038/leu.2013.339.
    1. Shimada A, Taki T, Tabuchi K, et al. KIT mutations, and not FLT3 internal tandem duplication, are strongly associated with a poor prognosis in pediatric acute myeloid leukemia with t(8;21): a study of the Japanese Childhood AML Cooperative Study Group[J] Blood. 2006;107(5):1806–1809. doi: 10.1182/blood-2005-08-3408.
    1. Pittoni P, Piconese S, Tripodo C, et al. Tumor-intrinsic and - extrinsic roles of c-Kit: mast cells as the primary off-target of tyrosine kinase inhibitors[J] Oncogene. 2011;30(7):757–769. doi: 10.1038/onc.2010.494.
    1. Walter RB, Kantarjian HM, Huang X, et al. Effect of complete remission and responses less than complete remission on survival in acute myeloid leukemia: a combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M. D. Anderson Cancer Center Study[J] J Clin Oncol. 2010;28(10):1766–1771. doi: 10.1200/JCO.2009.25.1066.
    1. de Rooij JD, Zwaan CM, van den Heuvel-Eibrink M. Pediatric AML: From Biology to Clinical Management[J] J Clin Med. 2015;4(1):127–149. doi: 10.3390/jcm4010127.
    1. Bhatt VR, Kantarjian H, Cortes JE, et al. Therapy of core binding factor acute myeloid leukemia: incremental improvements toward better long-term results[J] Clin Lymphoma Myeloma Leuk. 2013;13(2):153–158. doi: 10.1016/j.clml.2012.11.006.
    1. Schlenk RF, Benner A, Krauter J, et al. Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup[J] J Clin Oncol. 2004;22(18):3741–3750. doi: 10.1200/JCO.2004.03.012.
    1. Hsiao HH, Liu YC, Wang HC, et al. Additional chromosomal abnormalities in core-binding factor acute myeloid leukemia[J] Genet Mol Res. 2015;14(4):17028–17033. doi: 10.4238/2015.December.16.3.
    1. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties[J] Blood. 1998;92(7):2322–2333.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi